Who can use pemazyre(pemigatinib)?

Cholangiocarcinoma

Pemigatinib is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma that is unresectable, has received prior treatment, and harbors fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements detected by an FDA-approved test.

Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Pemigatinib is indicated for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLN) harboring fibroblast growth factor receptor 1 (FGFR1) rearrangements.

pemazyre(pemigatinib)

1. Cholangiocarcinoma 2. Myeloid/lymphoid neoplasms with FGFR1 rearrangement

CATEGORY NAVIGATION

RELATED ARTICLES

What is Pemazyre (Pemigatinib)?

Pemazyre (pemigatinib) is a targeted therapy drug approved for marketing by the U.S. FDA in 2020. It belongs to the...

Thursday, September 4th, 2025, 16:57

What is Pemazyre (Pemigatinib)?

Pemazyre (pemigatinib) is a targeted therapeutic drug approved for marketing by the U.S. FDA in 2020. It belongs to...

Thursday, September 4th, 2025, 16:40

Targeted Mechanism of Action of Pemigatinib

Pemigatinib is a novel targeted drug used for the treatment of cholangiocarcinoma and myeloid/lymphoid neoplasms. By...

Tuesday, September 2nd, 2025, 17:13

Departments

Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology

Contact Medical Consultant

Global Drug Search

Clinical recruitment

overseas medical treatment

Remote consultation

Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.

Click to submit medical consultant

Contact Us

Mailbox:Info@Lucius.La

Welcome To Consult

Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved